Allied Market Research
Loading...
0
New
New
2021
Lung Injury Market

Lung injury Market by Therapy (Medication and Devices), Injury Type (Direct Injury and Indirect Injury), and End User (Hospitals & Clinics and Others): Global Opportunity Analysis and Industry Forecast, 2021–2030

A13080
Pages: 208
Aug 2021 | 141 Views
   
Author(s) : Smita Nerkar , Onkar Sumant
Tables: 126
Charts: 45
  • Formats*:

  • SIngle User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • IComes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Lung Injury Market

Request Now !

Lung injury Market Overview 2030

The global lung injury market size was valued at $1,579.47 Million in 2020, and is projected to reach $2,417.41 Million by 2030 registering a CAGR of 4.20% from 2021 to 2030. Lung injury is an inflammatory condition that disrupts the endothelium and epithelial barriers in the lungs. ALI and ARDS are life-threatening forms of respiratory failure characterized by diffuse bilateral lung damage and severe hypoxemia produced by noncardiogenic pulmonary edoema. In addition, it is a key reason of mortality and morbidity in critically ill patients without any evidence of hydrostatic pulmonary edema. Symptoms observed in acute lung injury include severe shortness of breath, low blood pressure, confusion, and extreme tiredness. This type of injury has a significant impact on public health, with high incidence rate across the world. Moreover, it requires administration of rapid and goal-oriented therapy to prevent further lung damage.

The growth of the global lung injury market is majorly driven by rise in prevalence of lung-related diseases and increase in geriatric population. Furthermore, increase in awareness related to treatment of acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) is expected to notably contribute toward the growth of the global lung injury market. However, complications associated with the use of therapies and low adoption rate due to these complications hinder the market growth. On the contrary, pipeline drugs for the treatment of acute lung injury market are being studied in late phase of clinical trials. . These drugs are likely to be available in the market in next few years, which is expected to offer remunerative opportunity for the expansion of the market during the forecast period.

Lung-Injury-Market

Get more information on this report : Request Sample Pages

The outbreak of COVID-19 has disrupted workflows in the healthcare sector across the world. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of healthcare. Moreover, COVID-19 has positively impacted the lung injury market. When COVID-19 was first identified, many researchers redirected their focus to the study of this novel virus and the disease it causes. Severe COVID‐19 represents viral pneumonia from severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, which leads to acute respiratory distress syndrome. Its appearances can be viewed as a combination of the two processes that is viral pneumonia and acute respiratory distress syndrome. SARS‐CoV‐2 represents an ongoing worldwide threat, as this virus family has the potential to mutate and infect non‐immune population. Furthermore, patients with acute respiratory distress syndrome are often incapable to breathe on their own and may require ventilator support to help circulate oxygen in the body. Patients infected with the new coronavirus suffer from severe respiratory failure. For instance, approximately 30% of COVID-19 patients further develop life-threatening acute respiratory distress syndrome resulting in high mortality rate. In severe cases, COVID-19 can be complicated by the acute respiratory distress syndrome, sepsis & septic shock, multiorgan failure, including acute kidney injury and cardiac injury. Furthermore, older age and comorbid disease patients have been reported as risk factors for death. Till date, no medicine has been approved for the therapeutic treatment of severe COVID-19 and acute respiratory distress syndrome.

Lung Injury Market Segmentation  

The global lung injury market is segmented into therapy, injury type, end user, and region. Depending on therapy, the market is bifurcated into medication and devices. The medication segment is further categorized into pharmacotherapy, fluid management, and inhaled nitric oxide. Moreover, the devices is subdivided into mechanical ventilation and adjunctive procedures devices. On the basis of injury type, the market is segregated into direct injury and indirect injury. By end user, it is fragmented into hospitals & clinics, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Lung injury Market
By Product

Your browser does not support the canvas element.

Direct Injury segment is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

Segment Review

On the basis of therapy, the medication segment was the major shareholder 2020, as various therapies were used as supportive treatment for lung injury. Depending on injury type, the direct injury acquired the largest share in 2020, and is expected to remain dominant throughout the forecast period. This is attributed to rise in incidence of pulmonary infections worldwide.

Lung injury Market
By Therapy

Your browser does not support the canvas element.

Medication segment holds a dominant position in 2020 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Snapshot of Asia-Pacific Lung injury market  

Asia-Pacific accounted for the largest share of the global lung injury market in 2020, and is expected to remain dominant throughout the forecast period. This is attributed to the presence of large population base, increase in awareness associated with lung injury treatment, and rise in healthcare expenditure. 

Furthermore, surge in incidence of pulmonary infections in the region, which require the use of medications and devices for treatment of lung injury drives the growth of the market in this region.

Lung injury Market
By Region

2030
Asia-pacific 
North America
Europe
Lamea

Asia-Pacific region would exhibit the highest CAGR of 5.5% during 2021-2030.

Get more information on this report : Request Sample Pages

List Of Key Companies

  • Apeptico Forschung Und Entwicklung GmBH
  • Bayer AG
  • General Electric Company
  • Glaxosmithkline Plc, 
  • Koninklijke Philips N.V.
  • Linde Plc.
  • Medtronic Plc.
  • Ony Biotech Inc
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.

Key Benefits For Stakeholders

  • The study provides an in-depth analysis of the global lung injury market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
  • Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing lung injury market opportunities.
  • Extensive analysis of the key segments of the industry helps to understand the application and products the market used across the globe.
  • Key market players and their strategies have been analyzed to understand the competitive outlook of the lung injury market.

Key Market Segments

By Therapy

  • Medication
    • Pharmacotherapy 
    • Fluid Management 
    • Inhaled nitric oxide
  • Devices
    • Mechanical Ventilation
    • Adjunctive Procedures Devices 

By Injury Type

  • Direct Injury
  • Indirect Injury

By End User

  • Hospitals & Clinics
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China 
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Porter’s five force analysis
3.4.Top player positioning, 2020
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Rise in prevalence of lung-related diseases
3.5.1.2.Surge in geriatric population
3.5.1.3.Increase in adoption of new technologies with availability of high number of drugs used in lung injury treatment
3.5.1.4.Recent advancements in research related to treatment of acute lung injury

3.5.2.Restraint

3.5.2.1.High cost of therapies coupled with lack of established treatment

3.5.3.Opportunity

3.5.3.1.New developments in therapies

3.5.4.Impact analysis

3.6.COVID-19 impact analysis on the lung injury market

CHAPTER 4:LUNG INJURY MARKET, BY THERAPY

4.1.Overview

4.1.1.Market size and forecast

4.2.Medication

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.2.4.Market size and forecast, by type

4.2.4.1.Pharmacotherapy

4.2.4.1.1.Market size and forecast
4.2.4.1.2.Lung injury pharmacotherapy market size and forecast, by region
4.2.4.1.3.Lung injury pharmacotherapy market size and forecast, by country

4.2.4.2.Fluid management

4.2.4.2.1.Market size and forecast
4.2.4.2.2.Lung injury fluid management market size and forecast, by region
4.2.4.2.3.Lung injury fluid management market size and forecast, by country

4.2.4.3.Inhaled nitric oxide

4.2.4.3.1.Market size and forecast
4.2.4.3.2.Lung injury inhaled nitric oxide market size and forecast, by region
4.2.4.3.3.Lung injury Inhaled nitric oxide market size and forecast, by country

4.3.Devices

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.3.4.Market size and forecast, by type

4.3.4.1.Mechanical ventilation

4.3.4.1.1.Market size and forecast
4.3.4.1.2.Lung injury mechanical ventilation market size and forecast, by region
4.3.4.1.3.Lung injury mechanical ventilation market size and forecast, by country

4.3.4.2.Adjunctive procedures devices

4.3.4.2.1.Market size and forecast
4.3.4.2.2.Lung injury adjunctive procedures devices market size and forecast, by region
4.3.4.2.3.Lung injury adjunctive procedures devices market size and forecast, by country

CHAPTER 5:LUNG INJURY MARKET, BY INURY TYPE

5.1.Overview

5.1.1.Market size and forecast

5.2.Direct injury

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country

5.3.Indirect injury

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

CHAPTER 6:LUNG INJURY MARKET, BY END USER

6.1.Overview

6.1.1.Market size and forecast

6.2.Hospitals & clinics

6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country

6.3.Others

6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country

CHAPTER 7:LUNG INJURY MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by country

7.2.2.1.U.S. lung injury market, by therapy
7.2.2.2.U.S. lung injury market, by injury type
7.2.2.3.U.S. lung injury market, by end user
7.2.2.4.Canada lung injury market, by therapy
7.2.2.5.Canada lung injury market, by injury type
7.2.2.6.Canada lung injury market, by end user
7.2.2.7.Mexico lung injury market, by therapy
7.2.2.8.Mexico lung injury market, by injury type
7.2.2.9.Mexico lung injury market, by end user

7.3.Europe

7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by country

7.3.2.1.Germany lung injury market, by therapy
7.3.2.2.Germany lung injury market, by injury type
7.3.2.3.Germany lung injury market, by end user
7.3.2.4.France lung injury market, by therapy
7.3.2.5.France lung injury market, by injury type
7.3.2.6.France lung injury market, by end user
7.3.2.7.UK lung injury market, by therapy
7.3.2.8.UK lung injury market, by injury type
7.3.2.9.UK lung injury market, by end user
7.3.2.10.Italy lung injury market, by therapy
7.3.2.11.Italy lung injury market, by injury type
7.3.2.12.Italy lung injury market, by end user
7.3.2.13.Spain lung injury market, by therapy
7.3.2.14.Spain lung injury market, by injury type
7.3.2.15.Spain lung injury market, by end user
7.3.2.16.Rest of Europe lung injury market, by therapy
7.3.2.17.Rest of Europe lung injury market, by injury type
7.3.2.18.Rest of Europe lung injury market, by end user

7.3.3.Europe lung injury market, by therapy
7.3.4.Europe lung injury market, by injury type
7.3.5.Europe lung injury market, by end user

7.4.Asia-Pacific

7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by country

7.4.2.1.Japan lung injury market, by therapy
7.4.2.2.Japan lung injury market, by injury type
7.4.2.3.Japan lung injury market, by end user
7.4.2.4.China lung injury market, by therapy
7.4.2.5.China lung injury market, by injury type
7.4.2.6.China lung injury market, by end user
7.4.2.7.Australia lung injury market, by therapy
7.4.2.8.Australia lung injury market, by injury type
7.4.2.9.Australia lung injury market, by end user
7.4.2.10.India lung injury market, by therapy
7.4.2.11.India lung injury market, by injury type
7.4.2.12.India lung injury market, by end user
7.4.2.13.South Korea lung injury market, by therapy
7.4.2.14.South Korea lung injury market, by injury type
7.4.2.15.South Korea lung injury market, by end user
7.4.2.16.Rest of Asia-Pacific lung injury market, by therapy
7.4.2.17.Rest of Asia-Pacific lung injury market, by injury type
7.4.2.18.Rest of Asia-Pacific lung injury market, by end user

7.4.3.Asia-Pacific lung injury market, by therapy
7.4.4.Asia-Pacific lung injury market, by injury type
7.4.5.Asia-Pacific lung injury market, by end user

7.5.LAMEA

7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by country

7.5.2.1.Brazil lung injury market, by therapy
7.5.2.2.Brazil lung injury market, by injury type
7.5.2.3.Brazil lung injury market, by end user
7.5.2.4.Saudi Arabia lung injury market, by therapy
7.5.2.5.Saudi Arabia lung injury market, by injury type
7.5.2.6.Saudi Arabia lung injury market, by end user
7.5.2.7.South Africa lung injury market, by therapy
7.5.2.8.South Africa lung injury market, by injury type
7.5.2.9.South Africa lung injury market, by end user
7.5.2.10.Rest of LAMEA lung injury market, by therapy
7.5.2.11.Rest of LAMEA lung injury market, by injury type
7.5.2.12.Rest of LAMEA lung injury market, by end user

7.5.3.LAMEA lung injury market, by therapy
7.5.4.LAMEA lung injury market, by injury type
7.5.5.LAMEA lung injury market, by end user

CHAPTER 8:COMPANY PROFILES

8.1.APEPTICO FORSCHUNG UND ENTWICKLUNG GMBH

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Key strategic moves and developments

8.2.BAYER AG

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments

8.3.GENERAL ELECTRIC COMPANY

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance

8.4.GLAXOSMITHKLINE PLC.

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance

8.5.KONINKLIJKE PHILIPS N.V

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.5.6.Key strategic moves and developments

8.6.LINDE PLC

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance

8.7.MEDTRONIC PLC.

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance

8.8.ONY BIOTECH INC.

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio

8.9.PFIZER INC.

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance

8.10.TEVA PHARMACEUTICAL INDUSTRIES LTD.

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance

LIST OF TABLES

TABLE 01.LIST OF PIPELINE DRUGS CURRENTLY STUDIED/REGISTERED IN THE CLINICAL TRIAL FOR ACUTE LUNG INJURY OR ACUTE RESPIRATORY STRESS DISORDER IN COVID-19
TABLE 02.LUNG INJURY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 03.MEDICATION LUNG INJURY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 04.LUNG INJURY MEDICATION MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 05.LUNG INJURY PHARMACOTHERAPY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 06.LUNG INJURY PHARMACOTHERAPY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 07.LUNG INJURY FLUID MANAGEMENT MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 08.LUNG INJURY FLUID MANAGEMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 09.LUNG INJURY INHALED NITRIC OXIDE MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 10.LUNG INJURY INHALED NITRIC OXIDE MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 11.LUNG INJURY DEVICES MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 12.LUNG INJURY DEVICES MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 13.LUNG INJURY MECHANICAL VENTILATION MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 14.LUNG INJURY MECHANICAL VENTILATION MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 15.LUNG INJURY ADJUNCTIVE PROCEDURES DEVICES MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 16.LUNG INJURY ADJUNCTIVE PROCEDURES DEVICES MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 17.LUNG INJURY MARKET, BY INJURY TYPE, 2020-2030 ($MILLION)
TABLE 18.DIRECT LUNG INJURY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 19.INDIRECT LUNG INJURY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 20.LUNG INJURY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 21.LUNG INJURY MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020-2030 ($MILLION)
TABLE 22.LUNG INJURY MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
TABLE 23.LUNG INJURY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 24.NORTH AMERICA LUNG INJURY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 25.U.S. LUNG INJURY MARKET, BY THERAPY, 2020–2030
TABLE 26.U.S. LUNG INJURY MARKET, BY INJURY TYPE, 2020–2030
TABLE 27.U.S. LUNG INJURY MARKET, BY END USER, 2020–2030
TABLE 28.CANADA LUNG INJURY MARKET, BY THERAPY, 2020–2030
TABLE 29.CANADA LUNG INJURY MARKET, BY INJURY TYPE, 2020–2030
TABLE 30.CANADA LUNG INJURY MARKET, BY END USER, 2020–2030
TABLE 31.MEXICO LUNG INJURY MARKET, BY THERAPY, 2020–2030
TABLE 32.MEXICO LUNG INJURY MARKET, BY INJURY TYPE, 2020–2030
TABLE 33.MEXICO LUNG INJURY MARKET, BY END USER, 2020–2030
TABLE 34.EUROPE LUNG INJURY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 35.GERMANY LUNG INJURY MARKET, BY THERAPY, 2020–2030
TABLE 36.GERMANY LUNG INJURY MARKET, BY INJURY TYPE, 2020–2030
TABLE 37.GERMANY LUNG INJURY MARKET, BY END USER, 2020–2030
TABLE 38.FRANCE LUNG INJURY MARKET, BY THERAPY, 2020–2030
TABLE 39.FRANCE LUNG INJURY MARKET, BY INJURY TYPE, 2020–2030
TABLE 40.FRANCE LUNG INJURY MARKET, BY END USER, 2020–2030
TABLE 41.UK LUNG INJURY MARKET, BY THERAPY, 2020–2030
TABLE 42.UKLUNG INJURY MARKET, BY INJURY TYPE, 2020–2030
TABLE 43.UK LUNG INJURY MARKET, BY END USER, 2020–2030
TABLE 44.ITALY LUNG INJURY MARKET, BY THERAPY, 2020–2030
TABLE 45.ITALY LUNG INJURY MARKET, BY INJURY TYPE, 2020–2030
TABLE 46.ITALY LUNG INJURY MARKET, BY END USER, 2020–2030
TABLE 47.SPAIN LUNG INJURY MARKET, BY THERAPY, 2020–2030
TABLE 48.SPAIN LUNG INJURY MARKET, BY INJURY TYPE, 2020–2030
TABLE 49.SPAIN LUNG INJURY MARKET, BY END USER, 2020–2030
TABLE 50.REST OF EUROPE LUNG INJURY MARKET, BY THERAPY, 2020–2030
TABLE 51.REST OF EUROPE LUNG INJURY MARKET, BY INJURY TYPE, 2020–2030
TABLE 52.REST OF EUROPE LUNG INJURY MARKET, BY END USER, 2020–2030
TABLE 53.EUROPE LUNG INJURY MARKET, BY THERAPY, 2020–2030
TABLE 54.EUROPE LUNG INJURY MARKET, BY INJURY TYPE, 2020–2030
TABLE 55.EUROPE LUNG INJURY MARKET, BY END USER, 2020–2030
TABLE 56.ASIA-PACIFIC LUNG INJURY MARKET, BY COUNTRY, 2020-2030($MILLION)
TABLE 57.JAPAN LUNG INJURY MARKET, BY THERAPY, 2020–2030
TABLE 58.JAPAN LUNG INJURY MARKET, BY INJURY TYPE, 2020–2030
TABLE 59.JAPAN LUNG INJURY MARKET, BY END USER, 2020–2030
TABLE 60.CHINA LUNG INJURY MARKET, BY THERAPY, 2020–2030
TABLE 61.CHINA LUNG INJURY MARKET, BY INJURY TYPE, 2020–2030
TABLE 62.CHINA LUNG INJURY MARKET, BY END USER, 2020–2030
TABLE 63.AUSTRALIA LUNG INJURY MARKET, BY THERAPY, 2020–2030
TABLE 64.AUSTRALIA LUNG INJURY MARKET, BY INJURY TYPE, 2020–2030
TABLE 65.AUSTRALIA LUNG INJURY MARKET, BY END USER, 2020–2030
TABLE 66.INDIA LUNG INJURY MARKET, BY THERAPY, 2020–2030
TABLE 67.INDIA LUNG INJURY MARKET, BY INJURY TYPE, 2020–2030
TABLE 68.INDIA LUNG INJURY MARKET, BY END USER, 2020–2030
TABLE 69.SOUTH KOREA LUNG INJURY MARKET, BY THERAPY, 2020–2030
TABLE 70.SOUTH KOREA LUNG INJURY MARKET, BY INJURY TYPE, 2020–2030
TABLE 71.SOUTH KOREA LUNG INJURY MARKET, BY END USER, 2020–2030
TABLE 72.REST OF ASIA-PACIFIC LUNG INJURY MARKET, BY THERAPY, 2020–2030
TABLE 73.REST OF ASIA-PACIFIC LUNG INJURY MARKET, BY INJURY TYPE, 2020–2030
TABLE 74.REST OF ASIA-PACIFIC LUNG INJURY MARKET, BY END USER, 2020–2030
TABLE 75.ASIA-PACIFIC LUNG INJURY MARKET, BY THERAPY, 2020–2030
TABLE 76.ASIA-PACIFIC LUNG INJURY MARKET, BY INJURY TYPE, 2020–2030
TABLE 77.ASIA-PACIFIC LUNG INJURY MARKET, BY END USER, 2020–2030
TABLE 78.LAMEA LUNG INJURY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 79.BRAZIL LUNG INJURY MARKET, BY THERAPY, 2020–2030
TABLE 80.BRAZIL LUNG INJURY MARKET, BY INJURY TYPE, 2020–2030
TABLE 81.BRAZIL LUNG INJURY MARKET, BY END USER, 2020–2030
TABLE 82.SAUDI ARABIA LUNG INJURY MARKET, BY THERAPY, 2020–2030
TABLE 83.SAUDI ARABIA LUNG INJURY MARKET, BY INJURY TYPE, 2020–2030
TABLE 84.SAUDI ARABIA LUNG INJURY MARKET, BY END USER, 2020–2030
TABLE 85.SOUTH AFRICA LUNG INJURY MARKET, BY THERAPY, 2020–2030
TABLE 86.SOUTH AFRICA LUNG INJURY MARKET, BY INJURY TYPE, 2020–2030
TABLE 87.SOUTH AFRICA LUNG INJURY MARKET, BY END USER, 2020–2030
TABLE 88.REST OF LAMEA LUNG INJURY MARKET, BY THERAPY, 2020–2030
TABLE 89.REST OF LAMEA LUNG INJURY MARKET, BY INJURY TYPE, 2020–2030
TABLE 90.REST OF LAMEA LUNG INJURY MARKET, BY END USER, 2020–2030
TABLE 91.LAMEA LUNG INJURY MARKET, BY THERAPY, 2020–2030
TABLE 92.LAMEA LUNG INJURY MARKET, BY INJURY TYPE, 2020–2030
TABLE 93.LAMEA LUNG INJURY MARKET, BY END USER, 2020–2030
TABLE 94.APEPTICO: COMPANY SNAPSHOT
TABLE 95.APEPTICO: OPERATING SEGMENTS
TABLE 96.APEPTICO: PRODUCT PORTFOLIO
TABLE 97.APEPTICO: KEY DEVELOPMENTS
TABLE 98.BAYER: COMPANY SNAPSHOT
TABLE 99.BAYER: OPERATING SEGMENTS
TABLE 100.BAYER: PRODUCT PORTFOLIO
TABLE 101.BAYER: KEY DEVELOPMENTS
TABLE 102.GE: COMPANY SNAPSHOT
TABLE 103.GE: PRODUCT SEGMENTS
TABLE 104.GE: PRODUCT PORTFOLIO
TABLE 105.GSK: COMPANY SNAPSHOT
TABLE 106.GSK: PRODUCT SEGMENTS
TABLE 107.GSK: PRODUCT PORTFOLIO
TABLE 108.PHILIPS: COMPANY SNAPSHOT
TABLE 109.PHILIPS: PRODUCT SEGMENTS
TABLE 110.PHILIPS: PRODUCT PORTFOLIO
TABLE 111.PHILIPS: KEY DEVELOPMENTS
TABLE 112.LINDE: COMPANY SNAPSHOT
TABLE 113.LINDE: OPERATING BUSINESS SEGMENTS
TABLE 114.LINDE: PRODUCT PORTFOLIO
TABLE 115.MEDTRONIC: COMPANY SNAPSHOT
TABLE 116.MEDTRONIC: OPERATING SEGMENTS
TABLE 117.MEDTRONIC: PRODUCT PORTFOLIO
TABLE 118.ONY: COMPANY SNAPSHOT
TABLE 119.ONY: OPERATING SEGMENTS
TABLE 120.ONY: PRODUCT PORTFOLIO
TABLE 121.PFIZER: COMPANY SNAPSHOT
TABLE 122.PFIZER: OPERATING BUSINESS SEGMENTS
TABLE 123.PFIZER: PRODUCT PORTFOLIO
TABLE 124.TEVA: COMPANY SNAPSHOT
TABLE 125.TEVA: OPERATING SEGMENTS
TABLE 126.TEVA: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.LUNG INJURY MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018–2021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018–2021 (%)
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018–2021
FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE THREAT OF SUBSTITUTES
FIGURE 09.MODERATE THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE COMPETITIVE RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF LUNG INJURY MEDICATION MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 14.LUNG INJURY PHARMACOTHERAPY MARKET, 2020–2030 ($MILLION)
FIGURE 15.LUNG INJURY FLUID MANAGEMENT MARKET, 2020–2030 ($MILLION)
FIGURE 16.LUNG INJURY INHALED NITRIC OXIDE MARKET, 2020–2030 ($MILLION)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF LUNG INJURY DEVICES MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 18.LUNG INJURY MECHANICAL VENTILATION MARKET, 2020–2030 ($MILLION)
FIGURE 19.LUNG INJURY ADJUNCTIVE PROCEDURES DEVICES (ECMO) MARKET, 2020–2030 ($MILLION)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF DIRECT LUNG INJURY MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 21.COMPARATIVE SHARE ANALYSIS OF INDIRECT LUNG INJURY MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 22.COMPARATIVE ANALYSIS OF LUNG INJURY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 23.COMPARATIVE ANALYSIS OF LUNG INJURY MARKET FOR OTHERS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 24.BAYER: NET SALES, 2018–2020 ($MILLION)
FIGURE 25.BAYER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 26.BAYER: REVENUE SHARE BY REGION, 2020(%)
FIGURE 27.GE: NET SALES, 2018–2020 ($MILLION)
FIGURE 28.GE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 29.GE: REVENUE SHARE BY REGION, 2020(%)
FIGURE 30.GSK: NET SALES, 2018–2020 ($MILLION)
FIGURE 31.GSK: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 32.GSK: REVENUE SHARE BY REGION, 2020(%)
FIGURE 33.PHILIPS: NET SALES, 2018–2020 ($MILLION)
FIGURE 34.PHILIPS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 35.PHILIPS: REVENUE SHARE BY REGION, 2020(%)
FIGURE 36.LINDE: NET SALES, 2018–2020 ($MILLION)
FIGURE 37.LINDE: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 38.MEDTRONIC: NET SALES, 2018–2020 ($MILLION)
FIGURE 39.MEDTRONIC: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 40.MEDTRONIC: REVENUE SHARE BY REGION, 2020(%)
FIGURE 41.PFIZER: NET SALES, 2018–2020 ($MILLION)
FIGURE 42.PFIZER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 43.TEVA: NET SALES, 2018–2020 ($MILLION)
FIGURE 44.TEVA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 45.TEVA: REVENUE SHARE BY REGION, 2020(%)

 
 

Lung injury is a severe condition caused by acute hypoxemic respiratory failure. It is a major reason of mortality and morbidity in critically ill patients without any evidence of hydrostatic pulmonary edema. Furthermore, this condition is marked by symptoms such as severe shortness of breath, confusion, low blood pressure, and extreme tiredness.

Furthermore, increase in the prevalence of lung-related diseases, surge in geriatric population, rise in awareness associated with the treatment of lung injury, and improvement of healthcare infrastructure in emerging economies are the major factors that augment the growth of the lung injury market. However, controversial outcomes with the use of medications and devices in the management and treatment of ALI or acute respiratory distress syndrome (ARDS) limit the demand for these products, thereby affecting the growth of the market. For instance, although mechanical ventilation is often a life-saving intervention, it exhibits potential complications, including pneumothorax, alveolar damage, ventilator-associated pneumonia, airway injury, and ventilator-associated tracheobronchitis.

PURCHASE OPTIONS

Start reading instantly ,This Report and over 13000+ thousand more Reports, Available with Avenue Library, T&C*

Call or Email us

U.S.-Canada
Toll-free :
+1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
FREQUENTLY ASKED QUESTIONS?
Our Report Looks Like This
 

A. On the basis of therapy, the medication segment was the major shareholder 2020, as various therapies were used as supportive treatment for lung injury. Depending on injury type, the direct injury acquired the largest share in 2020, and is expected to remain dominant throughout the forecast period. This is attributed to rise in incidence of pulmonary infections worldwide.

A. Rise in prevalence of lung-related diseases and increase in geriatric population. Furthermore, increase in awareness related to treatment of acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) is expected to notably contribute toward the growth of the global market.

A. The total market value of Lung Injury market is $1,579.47 million in 2020.

A. Top companies such as Apeptico Forschung Und Entwicklung GmBH, Bayer AG, General Electric Company, Glaxosmithkline Plc, Koninklijke Philips N.V., Linde Plc., Medtronic Plc., Ony Biotech Inc.Pfizer Inc. and Teva Pharmaceutical Industries Ltd. held a high market position in 2020.

A. Asia-Pacific accounted for the largest share of the global lung injury market in 2020, and is expected to remain dominant throughout the forecast period. This is attributed to the presence of large population base, increase in awareness associated with lung injury treatment, and rise in healthcare expenditure.

A. The forcast period for Lung Injury market is 2021 to 2030

A. The market value of Lung Injury market in 2021 is $5,893.53 million.

A. The base year is 2020 in Lung Injury market

Allied Market Research Allied Market Research Allied Market Research
RELATED TAGS
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Lung Injury Market

Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,712
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $4,125
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $6,168
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,929
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $10,663
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Erythropoietin Drugs Market

Global Opportunity Analysis and Industry Forecast, 2021–2028

Published in May 2021

Download Sample

Protein Therapeutics Market

Global Opportunity Analysis and Industry Forecast, 2017-2023

Published in Nov 2017

Download Sample

Surgical Equipment Market

Global Opportunity Analysis and Industry Forecast, 2020-2027

Published in Jan 2021

Download Sample

Medical Implant Market

Global Opportunity Analysis and Industry Forecast, 2020–2027

Published in Nov 2020

Download Sample

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers